THRU E-MAIL

May 11, 2020

The Secretary
BSE Ltd.
Phiroze Jeejeebhoy Towers
27th Floor, Dalal Street
Mumbai 400 023
corp.relations@bseindia.com

Dear Sir,

Re: Declaration under Regulation 30 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 - Krebs Biochemicals & Industries Ltd.- (Scrip code: BSE: 524518 and NSE: KREBSBIO)

Pursuant to Regulation 30(1) and 30(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we are enclosing herewith our annual disclosure under Regulation 30(3) of the said Regulation in respect of shareholding held by us in Krebs Biochemicals & Industries Limited as Promoters/PAC for the financial year of the company ended 31st March, 2020.

Pursuant to Regulation 31 (4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we hereby declare that we have not made any encumbrance, directly or indirectly, on these shares other than those already disclosed during the financial year.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully
For Ipca Laboratories Limited

Harish Kamath
Corporate Counsel & Company Secretary

Encl: a/a

Cc: 1. The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Flr, Plot # C/1
G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051
takeover@nse.co.in

2. Krebs Biochemicals and Industries Limited
Plot No. 34, 8-2-577/B, Maas Heights,
Road No. 8, Banjara Hills, Hyderabad 500034
com_sec@krebsbiochem.com

Format for disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Part A- Details of shareholding

1. Name of the Target Company	Krebs Biochemicals& Industries Limited		
2. Names of the Stock Exchanges where the shares of the TC are listed	1. BSE Limited 2. National Stock Exchange of India Limited		
3. Particulars of the shareholder(s): a. Name of the person(s) together with Persons Acting in Concert (PAC) whose total (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. Or b. Name(s) of the promoter(s), member of the promoter group and PAC with him	Ipca Laboratories Limited		
4. Particulars of the shareholding of the person(s) mentioned at (3) above	Number of shares	% w.r.t total share/voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on 31st March, 2020 , holding of			
a) Shares	7145195	39.69%	33.14%
b) Voting rights (otherwise than by shares)	-	-	-
c) Warrants (convertible into shares)	3560000	-	16.51%
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
Total	10705195	-	49.65%

(*) Subject to conversion of whole of the outstanding warrants held into equity shares of the TC.

Ipca Laboratories Ltd.
www.ipca.com
125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444
E: ipca@ipca.com CIN: L24239MH1949PLC007837

Part B

Name of the Target Company: Krebs Biochemicals& Industries Limited

Names of the person and Person Acting in Concert (PAC) with the person	Whether the person belongs to the promoter/promoter group
Ipca Laboratories Limited	Promoter

Pursuant to Regulation 31 (4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we hereby declare that we have not made any encumbrance, directly or indirectly, on these shares held by us in the TC other than those already disclosed during the financial year.

FOR IPCA LABORATORIES LIMITED

HARISH P. KAMATH
COMPANY SECRETARY

Signature of the Authorised Signatory

Place: Mumbai

Date: 11th May, 2020

Note: In case of Promoter(s) making disclosure under Regulation 30(2), no additional disclosure under Regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Ipca Laboratories Ltd.
www.ipca.com
125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444
E: ipca@ipca.com CIN: L24239MH1949PLC007837